| BASILEA N |
| Datum/Zeit | / |
| Diff. / Diff.(%) | - / |
| Geld | - |
| Brief | - |
| Eröffnung | - |
| Schluss Vortag | - |
| Tageshoch | - |
| Tagestief | - |
| Volumen [CHF] | - |
| Volumen [Stück] | |
| Preisfeststellungen | |
| ISIN | CH0011432447 |
| Wertpapier | BSLN |
| Börse | SIX Swiss Exchange |
| Typ | Aktie |
Andere Handelsplätze
| Börse | Aktuell | Volumen | |
|---|---|---|---|
| SIX Swiss Ex.. | 31,400 |  |
19.880 |
| London Domes.. | 31,40 | |
3.222 |
| Cboe Europe .. | 31,45 |  |
1.555 |
| Cboe Europe .. | 31,60 | |
1.204 |
| Turquoise | 31,45 | |
457 |
| Lang & Schwa.. | 30,05 | |
|
| Nasdaq Other.. | 41,0000 | 40 | |
| München | 32,300 | 0 | |
| Berlin | 32,100 | 0 | |
| Frankfurt | 32,2800 | 0 | |
| gettex | 32,340 | ||
| TradeGate | 30,300 | 33 | |
| EUREX | Optionen | ||
Nachrichten
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire
Realtime